STOCKS TELEGRAPH

Tag: tech

  • What is a Biotech Stock? Best Biotech Stocks to Invest in for the Long-Term

    What is a Biotech Stock? Best Biotech Stocks to Invest in for the Long-Term

    The biotech industry is poised for a resurgence, as scientists declare it to be the “golden age” of biotechnology.

    Remarkable scientific breakthroughs are opening unprecedented avenues for disease treatment and prevention.

    This presents a lucrative opportunity to enhance your investment portfolio by including valuable biotech stocks. But here the question arises what is a biotech stock?

    Fortunately, you don’t have to undertake extensive research or face the daunting task of identifying the best options.

    We have compiled a list of the top biotech stocks that hold the most promise for current investments. Seize the moment and make wise choices in this thriving sector.

    What Are Biotech Stocks?

    Biotech stocks are shares of companies operating in the biotechnology industry.

    Biotechnology is a field that applies biological and scientific principles to develop products and technologies for various industries.

    Those include healthcare, agriculture, and environmental preservation.

    Biotech companies often focus on areas such as pharmaceuticals, genetic engineering, medical devices, diagnostics, and bioinformatics.

    Knowing what is a biotech stock and investing in them allows individuals to participate in the growth and advancements of these companies.

    This will potentially benefit investors from their innovations and success.

    What Are Biotech Stocks

    What’s The Difference Between Biotech And Pharmaceuticals?

    While biotech and pharmaceuticals both operate within the healthcare industry, there are key differences between them.

    Pharmaceuticals typically refer to companies that develop and manufacture drugs using chemical synthesis.

    They often focus on small molecules and compounds synthesized in laboratories.

    In contrast, biotech companies utilize living organisms, such as cells or bacteria, to produce therapeutic proteins or develop treatments based on genetic engineering and manipulation.

    Biotech companies may also leverage cutting-edge technologies like gene therapy, RNA interference, or stem cell research.

    In essence, biotech companies harness the power of biology to create innovative therapies and solutions.

    Biotech Companies

    Biotech is a compelling investment opportunity, combining scientific advancements with economic potential.

    So here we have picked some of the best biotech stocks to be considered in 2023.

    1. Amgen Inc. (AMGN)

      In our quest of what is a biotech stock, the very first stock we have picked is Amgen Inc. (AMGN), a prominent American biopharmaceutical company.

      The company stands at the forefront of biologics and holds a significant position in global biotech markets.

      Their success can be attributed, in part, to their adeptness in mergers and acquisitions.

      In 2019, a partnership with Celgene resulted in the inclusion of Otezla in Amgen’s drug portfolio, while a 20.5% stake in BeiGene facilitated entry into the Chinese oncology market.

      The acquisition of Immunex Corporation granted access to the blockbuster drug Enbrel, and the recent purchase of Five Prime Therapeutics introduced the promising drug bemarituzumab.

      This strategic approach safeguards Amgen’s future growth despite forthcoming patent expirations.

      Amgen has formed a multi-year partnership with TScan Therapeutics to utilize TScan’s unique target discovery platform, TargetScan.

      The collaboration aims to identify the antigens that T cells recognize in Crohn’s disease patients.

      TScan will receive an upfront payment of $30 million and stands to earn more than $500 million through preclinical, clinical, regulatory, and commercial milestones, along with royalty payments.

      Amgen will explore various modalities for developing therapeutics based on the identified targets and will hold exclusive global rights for development and commercialization.

      Additionally, Amgen has the option to extend the collaboration to include ulcerative colitis, subject to specific conditions.

      Amgen stands out on our list due to its robust financial profile and its performance in the recently reported quarter.

      Despite a minor 2% decline in sales at $6.1 billion, its earnings soared by an impressive 97% to $5.28 per share.

      Moreover, the company offers an attractive dividend yield of 3.83%.

      With a combination of these strengths and a stable price over the last three months, Amgen emerges as an excellent biotech stock to consider adding to your portfolio.

    2. Biogen Inc. (BIIB)

      Biogen Inc. (BIIB), a prominent biotech company based in the United States, takes its place on our list of noteworthy biotech stocks.

      Despite the controversies surrounding its drug Aduhelm and the intensifying competition from generic alternatives, Biogen cannot be overlooked.

      In a recent development, Biogen, in collaboration with Eisai Co., Ltd., announced a significant achievement.

      The Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) of the U.S. Food and Drug Administration (FDA) unanimously validated the efficacy of LEQEMBI.

      The drug is also known as lecanemab and is used in treating Alzheimer’s disease (AD).

      The committee’s evaluation was based on the conclusive data from Eisai’s Phase 3 Clarity AD clinical trial.

      LEQEMBI, a result of the strategic research alliance between Eisai and BioArctic, demonstrated a favorable overall benefit-risk profile, as affirmed by the committee members.

      Notably, the drug’s marketing authorization application has been submitted to the Ministry of Food and Drug Safety (MFDS) in South Korea.

      This marks the first application for lecanemab in Asia outside of Japan and China. Eisai intends to file additional applications in various Asian countries.

      Furthermore, Health Canada has accepted a New Drug Submission (NDS) for LEQEMBI, acknowledging its potential and significance in the healthcare landscape.What is a Biotech Stock

      Despite the expiration of the Tecfidera patent and increased generic competition, Biogen remains financially strong.

      Last quarter, the company’s earnings surged 30% to $387.9 million ($2.67 per share).

      Although the cash balance decreased by 18% to $2.9 billion, sales reached $2.46 billion, surpassing expectations despite a slight decline.

      With a share price up by almost 56% since last year, Biogen is an attractive stock to consider adding to your portfolio and holding onto.

    3. Bio-Techne Corporation (TECH)

      As part of our journey to discover what is a biotech stock, we are adding Bio-Techne (TECH) to our stock lineup.

      This U.S.-based biotech company specializes in supplying life science reagents, instruments, and services to global research, diagnostics, and Bioprocessing markets.

      Unlike other biotech firms on our list, Bio-Techne offers investors a gateway into the thriving genomics industry, predicted to grow at an impressive 16.87% by 2030 to $98.7 billion.

      With a rich legacy of innovation, Bio-Techne has amassed an extensive array of proteomic research reagents, empowering groundbreaking scientific breakthroughs.

      This exceptional feature further enhances the appeal of investing in this biotech gem. In spite of its already substantial presence, Bio-Techne continues to forge ahead with its expansion efforts.

      One recent endeavor involved the augmentation of their Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio.

      That was through the introduction of an RNAscope multiomic workflow compatible with the Standard BioTools Hyperion Imaging System.

      The integration of multiomic spatial imaging into the Hyperion Imaging System presents an unprecedented opportunity to generate intricate and comprehensive tissue architectural maps.

      It establishes connections between transcripts, proteins, and signaling networks within tissues.

      The technology enables the assessment of drug efficacy, the discovery of innovative intervention methods, and the identification of informative biomarkers.

      Consequently, it possesses the potential to become a cornerstone of precision medicine approaches in the future.

      Moreover, Bio-Techne boasts an appealing financial profile, including a dividend payout of 0.43%.

      During their most recent fiscal quarter, which concluded on March 31, 2023, the company achieved organic revenue of $294.1 million, marking a respectable 3% year-over-year growth.

      Additionally, quarterly earnings per share rose from $0.37 in the previous year to $0.43.

      Considering the substantial potential for growth, the reduced risk factor, and the company’s robust financial standing, investing in Bio-Techne stock is a highly favorable decision.

      Furthermore, the current market volatility has caused the stock to trade at a price that remains approximately 9.5% lower year-to-date, presenting an advantageous buying opportunity.

    4. Exelixis Inc (EXEL)

      Exelixis Inc (EXEL), a U.S.-based biotech company focused on oncology, stands out as a resilient player in the market.

      Nonetheless, Exelixis remains committed to its core objectives and has made substantial strides in advancing its commercial endeavors and expanding its pipeline.

      CABOMETYX is a leading tyrosine kinase inhibitor for renal cell carcinoma.

      It maintained its position in the first quarter, primarily attributed to its successful utilization in combination with nivolumab for first-line treatment.

      The company has also made notable progress across various pipeline programs, including the STELLAR-303 and STELLAR-304 Phase 3 trials for zanzalintinib.

      EXEL also progressed well as the phase 1 trial of XB002, exploring single-agent and combination dose-escalation cohorts.

      Exelixis aims to initiate pivotal studies for zanzalintinib in 2023 and expedite the full development of XB002 by year-end.

      Notably, the company has also achieved steady advancements through collaborations with Cybrexa and Sairopa.

      Sairopa received FDA clearance for its Investigational New Drug application for ADU-1805 in February, followed by the commencement of a phase 1 study in March.

      In terms of financials, Exelixis witnessed a 15% year-over-year revenue growth in Q1 2023, totaling $408.79 million.What is a Biotech Stock - Growth

      However, increased research and development (R&D) as well as selling, general, and administrative (SG&A) expenses led to a 40% decline in income, settling at $40 million.

      Looking ahead, the company anticipates full-year revenue ranging from $1.78 billion to $1.88 billion in 2023.

      Consequently, with a modest 7% price performance over the past 12 months, Exelixis presents an attractive opportunity for investors.

      It will not only diversify their portfolios but also offers a promising biotech stock poised for growth.

    5. Corcept Therapeutics Incorporated (CORT)

      Corcept Therapeutics (CORT) emerges as a prominent player in the biotech sector.

      It specializes in the development of drugs that effectively manage unstable cortisol levels and associated disorders.

      At the forefront of their product lineup is Korlym, a groundbreaking treatment approved for Cushing’s syndrome in type 2 diabetes patients.

      This drug holds orphan status and exclusive rights until 2037 for Cushing’s, and Corcept is diligently working towards securing approvals for additional indications.

      The potential for Korlym’s expansive market reach is immense, given its multiple applications.

      To further enhance physicians’ ability to identify and treat patients with hypercortisolism, CORT is making substantial investments.

      A noteworthy initiative is the recently established CATALYST study, which holds promise for significant growth in the field of Cushing’s syndrome treatment.

      From a financial standpoint, Corcept Therapeutics demonstrates exceptional performance.

      In the first quarter of 2023 alone, the company experienced a remarkable 13% revenue increase, amounting to $105.66 million.

      Moreover, Corcept boasts a net income of 15 cents per share, while maintaining a robust cash balance of $465.06 million by the end of the quarter.

      Notably, the company’s return on equity stands well above the industry average, at an impressive 19.40%.

      Considering the impressive progress in Corcept’s pipeline and its recent one-month price decline of 5%, an opportune moment arises for potential investors.

      With its proven track record, strong financial profile, and promising growth prospects, Corcept presents a compelling buying opportunity.

      CORT may also yield significant returns as the company’s stock price is poised to soar once again.

    To further explore what is a biotech stock and which are performing well, we have carefully selected 20 tickers here that represent the top 20 biotech stocks with outstanding performance, exceeding 80% YTD.

    These promising options are poised to make a significant impact in 2023, offering the potential for substantial returns.

    20 Best Performing Biotech Stocks
    No. Ticker Company Market Cap (in million) Performance (YTD) Price
    1 AMAM Ambrx Biopharma Inc. 788.28 556.22% 14.9
    2 GNLX Genelux Corporation 856.95 457.80% 34.31
    3 BMEA Biomea Fusion, Inc. 1407.4 336.89% 36.83
    4 IMGN ImmunoGen, Inc. 4163.14 273.08% 18.5
    5 PTGX Protagonist Therapeutics, Inc. 1659.44 161.96% 28.58
    6 MLTX MoonLake Immunotherapeutics 1410.18 161.19% 27.42
    7 IRON Disc Medicine Opco Inc 837.9 146.35% 49
    8 RETA Reata Pharmaceuticals, Inc. 3850.63 140.91% 91.52
    9 NVCT Nuvectis Pharma, Inc. 286.81 140.27% 18.02
    10 VKTX Viking Therapeutics, Inc. 2283.33 139.36% 22.5
    11 CBUS Cibus, Inc. 56.84 137.15% 17.49
    12 TGTX TG Therapeutics, Inc. 4285.47 126.29% 26.77
    13 MORF Morphic Holding, Inc. 2706.85 123.08% 59.67
    14 TYRA Tyra Biosciences, Inc. 642.07 116.91% 16.49
    15 VYGR Voyager Therapeutics, Inc. 555.08 111.23% 12.89
    16 BBIO BridgeBio Pharma, Inc. 2759.99 105.77% 15.68
    17 VECT VectivBio Holding AG 1047.68 93.25% 16.75
    18 HEPA Hepion Pharmaceuticals, Inc. 49.52 92.47% 11.56
    19 ELTX Elicio Therapeutics, Inc. 84.96 82.63% 14.82
    20 RXDX Prometheus Biosciences, Inc. 9549.57 81.77% 199.95

    We have also compiled a list of the 5 best biotech penny stocks which has performed well this year. These penny stocks could be a better investment opportunity for long term growth.

    These stocks are currently trading at relatively low prices and have the potential to generate good returns over time.

    Best Biotech Penny Stocks

    No. Ticker Company Market Cap (in million) Performance (YTD) Price
    1 VYNE VYNE Therapeutics Inc. 18.67 73.33% 4.68
    2 DBTX Decibel Therapeutics, Inc. 112.82 114.63% 4.4
    3 LSTA Lisata Therapeutics, Inc. 35.06 70.75% 4.32
    4 ASLN ASLAN Pharmaceuticals Limited 64.28 116.13% 3.89
    5 NAUT Nautilus Biotechnology, Inc. 426.56 112.78% 3.83

    Taking the exploration of what is a biotech stock a step further; we have compiled a list of some of the best biotech stocks under $1.

    These biotech stocks under $1 could prove to be a good investment for long term growth.

    The biotech stocks under $1 are currently trading at a relatively low price and may be able to generate good returns in the future.

    Best Biotech Stocks Under $1
    No. Ticker Company Market Cap (in million) Performance (YTD) Price
    1 EFTR eFFECTOR Therapeutics, Inc. 52.16 131.52% 0.99
    2 ERYP ERYTECH Pharma S.A. 32.19 142.35% 0.8
    3 PHGE BiomX Inc. 15.38 88.06% 0.35
    4 VBLT Vascular Biogenics Ltd. 18.99 102.58% 0.24
    5 ATOS Atossa Therapeutics, Inc. 113.96 67.70% 0.89

    What Drives Biotech Stocks?

    Several factors can drive the performance and volatility of biotech stocks:

    Examples Of Price Swings

    Biotech stocks are particularly sensitive to events such as clinical trial results, regulatory approvals, and market sentiment.

    Positive clinical trial data or regulatory milestones, such as receiving approval from the U.S. Food and Drug Administration (FDA), can significantly impact stock prices.

    Conversely, negative trial results or regulatory setbacks can lead to sharp declines.

    Additionally, broader market trends, investor sentiment toward the biotech sector, and the overall economic climate can also influence biotech stock prices.

    How To Invest In Biotechnology

    Investing in biotechnology can be done through various avenues:

    • How To Invest in Biotechnology Stocks?

      If you want to know how to invest in biotech stocks, it is better to purchase individual stocks of biotech companies.

      Before investing, it is crucial to research and analyze the financial health, product pipeline, and competitive position of the companies in consideration.

      Understanding the risks associated with the specific biotech sector and diversifying investments across multiple companies can help manage risk.

    • How To Invest in Biotechnology ETFs?

      Biotechnology-focused Exchange-Traded Funds (ETFs) offer a convenient and cost-effective way to gain exposure to the biotech sector.

      Investors in search of how to invest in biotech stocks can also use ETFs as an alternative and more promising option. ETFs offer a diversified approach to investing in the targeted sector.

      Biotech ETFs consist of a basket of biotech stocks, providing exposure to multiple companies within the industry.

      This approach can help reduce risk by spreading investments across different companies and potentially capturing broader industry trends.

    What’s The Outlook for Biotechnology?

    The outlook for biotechnology is generally positive due to ongoing advancements in healthcare, increasing demand for innovative treatments, and the potential for transformative discoveries.

    According to Data Bridge Market Research analyses, the global biotechnology market is expected to reach $10 trillion by 2030, at a compound annual growth rate (CAGR) of 29%.

    However, the industry can also face challenges related to clinical trials, regulatory hurdles, and competition.

    It is important to stay informed about the latest developments, regulatory changes, and market trends when considering investments in biotech.

    Risks Of Biotechnology Stocks

    Investing in biotech stocks involves certain risks that investors should be aware of:

    • Clinical Failure

      Biotech companies often conduct clinical trials to evaluate the safety and efficacy of their products.

      However, there is always a risk of clinical failure, where a drug or treatment does not meet the desired endpoints.

      Negative trial results can lead to significant stock price declines, as it may delay or halt the product’s development and commercialization.

    • Regulatory Issues

      Regulatory approval is a critical milestone for biotech companies. The FDA and other regulatory bodies have stringent requirements for safety and efficacy.Regulatory Issues

      Delays or rejections in obtaining approvals can negatively impact stock prices.

      Additionally, changes in regulations or unexpected adverse events related to approved products can also affect the performance of biotech stocks.

    Developing The Market

    Biotech companies face specific challenges in developing and commercializing their products including:

    • Patent Expiration

      Patents play a vital role in protecting the intellectual property of biotech companies.

      However, patents have limited lifespans, and once they expire, other companies can produce generic versions of the drug, potentially leading to a decline in sales and market share.

      Companies must continuously innovate and develop new products to stay competitive after patent expiration.

    Challenges With Researching Biotech Stocks

    Researching biotech stocks can be complex and challenging due to several factors:

    • Scientific Complexity

      Understanding the scientific concepts and technical aspects of biotech companies requires specialized knowledge and expertise.

    • Pipeline Evaluation

      Assessing the potential of a company’s product pipeline, clinical trial outcomes, and market prospects demands careful analysis and understanding of the regulatory landscape.

    • Volatility

      Biotech stocks can be highly volatile, making it challenging to predict future performance accurately.

    Best Online Brokers for Biotech Penny Stocks

    Investing in biotech penny stocks, which are low-priced stocks, typically involves higher risk and volatility.

    To better understand how to invest in biotech stocks online, it is important to choose reputable and reliable online brokers.

    Suitable brokers offer access to these stocks while providing robust trading platforms, research tools, and competitive pricing.

    Some popular online brokers known for their biotech offerings include Charles Schwab, TD Ameritrade, Fidelity, E*TRADE, and Interactive Brokers.

    However, it is advisable to conduct thorough research and consider individual preferences before selecting a specific broker.

    Conclusion

    In conclusion, biotech stocks offer investors an opportunity to participate in the advancements of the biotechnology industry.

    However, it is important to under what is a biotech stock and carefully evaluate the risks. Investors should also conduct thorough research, and stay informed about the latest developments in the sector before making investment decisions.

    Diversification, understanding the scientific and regulatory landscape, and staying abreast of market trends are crucial elements in navigating the biotech investment landscape.

    Frequently Asked Questions

    Which Biotech Penny Stocks Should I Buy?

    As an AI language model, I cannot provide real-time financial advice or stock recommendations.

    It is important to conduct thorough research and consult with a financial advisor before making any investment decisions.

    Biotech penny stocks can be highly volatile and risky, so it’s crucial to evaluate the company’s financials, pipeline, and market potential before investing.

    Is Biotech a Safe Investment?

    Biotech, a rapidly evolving field, presents opportunities and risks as an investment.

    While breakthroughs in healthcare, agriculture, and energy hold immense potential, regulatory challenges, clinical trial outcomes, and patent disputes introduce volatility.

    Thorough research, diversification, and understanding of industry dynamics are essential to navigate this complex landscape and make informed investment decisions.

  • Tilray Inc. (TLRY) Stock Surges Following Announcement of Promising Financial Reports for Fiscal Q4 2021

    Tilray Inc. (TLRY) stock prices were up 22.47% as of the market opening on July 28th, 2021, bringing the price per share up to USD$15.69 early on in the trading day.

    Net Revenue Breakdown

    Net revenue for the fourth quarter of fiscal 2021 was reported at USD$142.2 million, up 25% from the USD$113.5 million reported for the prior year quarter. The increase was largely driven by a 36% increase in net cannabis revenue, which was reported at USD$53.7 million. This included a four wee contribution from legacy-Tilray, a 10% decline in distribution revenue, and a net beverage alcohol revenue of USD$15.9 million as a result of TLRY stock’s acquisition of SweetWater on November 25th 2020. Also contributing to the year-over-year increase was wellness revenue in the amount of USD$5.8 million from Manitoba Harvest.

    Income and Adjusted EBITDA

    Net income for the 2021 quarter came in at USD$33.6 million, a massive improvement from the net loss of USD$84.3 million reported in the prior year quarter. Adjusted EBITDA was up to USD$12.3 million during the fourth quarter of 2021, representing a massive 285% increase from the USD$3.2 million reported in the prior-year quarter. This marks the ninth consecutive quarter of positive Adjusted EBITDA.

    TLRY Stock’s Gross Profits

    Gross Profits were down to USD$22.5 million for the quarter, a 19% decrease from the USD$27.8 million reported in the prior-year quarter. Gross profits for the quarter included a one-time inventory valuation adjustment of USD$19.9 million, derived from excess inventory quantities as of the business combination with Aphria. Adjusted gross profit was reported at USD$42.4 million, a 53% increase from the USD$27.8 million reported for Q4 2020.

    Ongoing Cost Synergies

    TLRY stock anticipates facilitating significant cost synergies amounting to a total of USD$80 million within eighteen months of closing its business combination with Aphria Tilray. These cost synergies are forecasted to be focused in the key areas of cultivation and production, cannabis and product purchasing, sales, and marketing, as well as corporate expenses. So far, the company has achieved USD$35 million in synergies.

    Future Outlook for TLRY

    Armed with the success of its most recent financial reports for the last quarter of fiscal 2021, TLRY is poised to continue its trajectory of success into the new year. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • Grove Inc. (GRVI) Stock Surges Following Announcement of Successful Fiscal 2021 Financial Reports

    Grove Inc. (GRVI) stock prices were up 35.54% as of the market opening on July 28th 2021, bringing the price per share up to USD$6.30 early on in the trading day.

    Revenue and Net Income Reports

    July 28th 2021 saw GRVI stock, the Nevada based company that is revolutionizing the hemp industry, report preliminary and unaudited financial results for the fourth quarter of fiscal 2021, ended June 30th 2021. The company reported revenues ranging from USD$10.1 million to USD$10.4 million, representing a massive 300% increases over the numbers reported for the prior year quarter. Net income is expected to range from USD$1.5 million to USD$2 million, up from a net loss of more than USD$700,000 in the fourth quarter of fiscal 2020.

    2021 Full Year Report

    GRVI stock reported expecting full year revenues for the full fiscal year in the amount of USD$23.6 million to USD$23.9 million, a substantial 200% increase over the USD$7.4 million reported for the fiscal year 2020. Net income for the 2021 year is expected to range from USD$2 million to USD$2.5 million, up from a considerable net loss of USD$5 million for the fiscal year 2020. Full financial results for the fiscal year 2021 are expected around September 15th 2021.

    GRVI Stock Exceeding Expectations

    The company is pleased to announce having exceeded all of its internal projections for growth and profitability over the course of 2021 so far. Driven by a combination of a stellar workforce and an effectively executed business strategy, the company continued to expand the scope of its growth while sustaining profitability.

    GRVI Stock Planning to Reinvest

    The company is keen to enter the fiscal year 2022 riding the momentum generated over the fiscal year 2021. The current years financial success afford the company flexibility in investing to further consolidate and enhance internal growth. A solid balance sheet and continued positive cash flow from operations will see the company invest heavily in facilitating the growth of GRVI stock’s Products and Manufacturing. Investments are also expected to be made in an Extraction and Lab Facility to pioneer the R&D in the Hemp and Wellness industries.

    Future Outlook for GRVI

    Armed with the immense success of its preliminary and unaudited financial reports for the fiscal year 2021, GRVI stock is poised to capitalize on its momentum. The company is keen to continue its trajectory of success into the new fiscal year, hoping to drive additional growth. Investors are hopeful that management will continue to execute its strategy so as to usher in further gains in shareholder value.

  • PolarityTE Inc. (PTE) Stock on the Rise Following Announcement of Positive Topline Data from SkinTE Clinical Trial

    PolarityTE Inc. (PTE) stock prices were up 4.84% as of the market opening on July 28th, 2021, bringing the price per share up to USD$0.85 early on in the trading day.

    SkinTE Clinical Trial

    July 28th, 2021 saw the company announce the final data from its multi-center, randomized, and controlled trial, designed to evaluate the treatment of Diabetic Foot Ulcers. PTE stock’s proprietary investigational product SkinTE, in combination with standard of care, was evaluated against just standard of care alone.

    PTE Stock’s Trial’s Success

    PTE stock reported having successfully met the primary endpoint of the trial of wound closure by the twelfth week of treatment. The secondary endpoint of Percent Area Reduction (PAR) was also met, having been assesses for every even-numbered week from the fourth to the twelfth. The trial had a total enrolment of 100 participants that were split into two equal groups, with one received SOC plus SkinTE, whereas the other cohort received only SOC. The trial was conducted and evaluated across 13 different sites.

    Trial Results

    35 out of the 50 patients, representing 70% of the cohort, who received SkinTE in conjunction with SOC exhibited wound closure at 12 weeks. This is comparable to the 17 patients out of 50, representing 34%, exhibiting wound closure by week 12 with SOC only. 45 out of the 50 patients who received the SkinTE plus SOC treatment received a single application of SkinTE. Treatment with SkinTE in tandem with SOC resulted in an increase in the odds of would closure by a massive 5.37 times versus SOC alone.

    Adverse Event Reports

    The trial reported 148 Adverse events that were attributable to 49 subjects. The SkinTE plus SOC treatment cohort reported 66 AEs among 21 subjects while the SOC treatment group reported 82 Adverse Events, attributable to 28 subjects. Of this total, 26 incidents were Serious Adverse Events, with 12 occurring in the SkinTE plus standard of care across 7 subjects. 14 Serious Adverse Events were reported for the standard of care cohort, allocated across a total of 9 subjects.

    Future Outlook for PTE Stock

    Armed with the resounding success of the results of its SkinTE clinical trial, PTE Stock is poised to capitalize on the opportunities for the proliferation of the treatment. The company is keen to allocate resources towards consolidating and expanding its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • electroCore Inc. (ECOR) Stock on the Rise Following Announcement of Newly Issued Patent

    electroCore Inc. (ECOR) stock prices were up 3.92% as of the market closing on July 27th, 2021, bringing the price per share up to USD$0.9665 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 5.54%, bringing it up to USD$1.02.

    ECOR Stock’s Patent

    July 27th, 2021 announced that the United States Patent and Trademark Office (USPTO) has granted ECOR stock U.S. Patent No. 11,065,444. The patent issued to the commercial-stage bioelectronic medicine company is in regard to the use of a mobile phone for the stimulation of the trigeminal nerve to treat disorders. The new patent is owned by the company and is the most recent U.S patent to be issued in connection with the company’s development of non-invasive solution programs for pain.

    Patented Technology

    The newly issued patent includes descriptions of devices and methods that can be used by patients themselves to treat medical conditions, such as migraine headaches, with non-invasive means. ECOR stock achieves this by the electrical stimulation of nerves in the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the general area of patients’ foramen or notch.

    About the Treatment

    The system consists of a handheld mobile device, like a smartphone, that is applied to the surface of the head of the patient being treated. Electrical impulses are applied through the patient’s skin via one or more electrodes, serving to modulate a targeted nerve to treat the medical condition. ECOR stock’s system aims to provide patients with a self-treatment solution in the absence of a medical professional.

    Expansive Scope of Treatment

    ECOR stock is keen to continue the advancement of its non-invasive treatment solutions for its patients. The new development massively increases the scope of the reach and accessibility by which the company’s therapy may be deployed. This facilitates more patients all over the world to get the relief they need while not having to leave the comfort of their homes. This is line with the company’s vision of improving patient outcomes with its nerve stimulation therapy platform, which initially focused on the treatment of various neurological conditions.

    Future Outlook for ECOR Stock

    Armed with the security of the patenting of its proprietary technology, ECOR stock is poised to capitalize on the opportunities and tenure afforded to it over the long term. The company is keen to spearhead market penetration in an effort to usher in significant and sustained increases in shareholder growth.

  • Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment

    Sintx Technologies, Inc. (SINT) stock prices were up 11.04% as of the market closing on July 27th, 2021, bringing the price per share up to USD$1.71 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.85%, bringing it down to USD$1.61.

    FleX SN-PEEK Shipments

    July 27th, 2021 saw SINT stock announce the first shipment of FleX SN-PEEK, its new product that is designed to be used in orthopedic implants. The company’s proprietary product commenced being shipped on July 20th, 2021, combining the singular bioactivity of silicon nitride with the properties of Zeniva PEEK, which was supplied by Solvay.

    About FleX SN-PEEK

    The composite material has been deemed to have a myriad of applications, ranging from spine surgery to joint replacements to craniomaxillofacial medical devices. On the basis of data collected by SINT stock on silicon nitride, FleX SN-PEEK is expected to facilitate faster bone healing, improved radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection as compared to PEEK in isolation.

    Advantages of FleX SN-PEEK

    The commencement of the shipping of SINT stock’s FleX SN-PEEK is a major milestone for the company. It continues to allocate resources to leverage the osteogenic and antipathogenic properties of silicon nitride for biomedical applications. The company is confident that the product differentiates itself as being superior with many unmatched benefits. Zaniva PEEK is a biomaterial that has been determined to have many advantages, signaled by its worldwide use. The advantages include favorable material modules, ease of manufacturing, established clinical record, as well as a track record of use in orthopedics.

    SINT Stock Healthcare Scope

    The combination of PEEK with silicon nitride’s osteogenic and antipathogenic properties gives rise to a superior product, FleX SN-PEEK. The catalogue of FleX SN-PEEK products provides access to new biomedical areas like craniomaxillofacial, and foot osteotomy and fusion. The proprietary technology serves to address a large unmet need stemming from surgeons constantly on the lookout for materials and procedures that result in improved outcomes with mitigated complications.

    Future Outlook for SINT

    Armed with the success of the first delivery of its proprietary technology, SINT stock is poised to capitalize on the continued development of FleX SN-PEEK. The company is keen to expand and consolidate its market footprint in order to continue its trajectory of success. Investors are hopeful that management will be able to allocate resources so as to ensure maximum gains in shareholder value.

  • Powerbridge Technologies Co., Ltd. (PBTS) Stock on the Rise Following Announcement of SCM SaaS Platform

    Powerbridge Technologies Co., Ltd. (PBTS) stock prices were up 7.94% as of the market close on July 26th, 2021, bringing the price per share up to USD$1.36 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 11.03%, bringing it up to USD$1.51.

    PBTS Stock’s Foray into Blockchain

    July 27th, 2021 saw the company reveal that it was in the process of building a Supply Chain Management SaaS platform that will be enabled by Blockchain technology. The company is keen to spearhead its foray into Blockchain technology in an effort to optimize and integrate traditional supply chain systems. PBTS stock is a cutting-edge tech company that focuses on providing artificial intelligence, the Internet of Things, Blockchain, and financial technologies.

    About the SaaS Platform

    The company also offers SaaS solutions and operational services in various fields such as cross-border trade, smart cities, and government services. PBTS stock’s Blockchain-enabled Supply Chain Management SaaS Platform is being designed to connect suppliers, logistics service providers, distributors, retailers, and end-users. It will do so with an integrative feature network, facilitating real-time information sharing for all participants. In doing so, the company ensures the credibility of the information and facilitates the efficiency of information transmission.

    Scope of Blockchain Technology

    PBTS stock hopes for its Blockchain management platform to prove to be applicable to more practical contexts, with a deep-rooted integration with businesses. The company intends to continue developing Blockchain applications and SaaS with more trials and innovations. The application of Blockchain technology is expected to generate sustained growth of PBTS’ revenue. PBTS will also expand its application to other fields, such as supply chain finance technology.

    About PBTS Stock

    With nearly 25 years of history behind it, PBTS stock aims to provide a myriad of smart-technology-based products and solutions. These offerings include global trade-related ports and customs management platforms, cross-border and global trade solutions, smart city tech products and solutions. The company also utilizes innovative technology such as Big Data, artificial intelligence, Blockchain, and the Internet of Things.

    Future Outlook for PBTS Stock

    Armed with its foray into the burgeoning blockchain market space, PBTS is poised to capitalize on its entry into a marketspace rife with opportunities. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • TRxADE HEALTH, Inc. (MEDS) Stock Dips Significantly Following Disclosure of Q2 2021 Financial Reports

    TRxADE HEALTH, Inc. (MEDS) stock prices were down 4.01% as of the market closing on July 26th, 2021, bringing the price per share down to USD$5.26 at the end of the trading day. Subsequent premarket fluctuations saw the stock plummet by 19.20%, bringing it down to USD$4.25.

    Expanding Consumer Base

    MEDS stock continued to allocate resources toward the expansion of its drug procurement marketplace over the course of Q2 2021. The quarter reported having added roughly 195 new registered members, bumping the total number of registered members up to more than 12,700. The company also signed various enterprise retail partnerships to onboard new customers to its telehealth platform, partnering up with the likes of Brookshire Grocery, Winn-Dixie, and Big Y. MEDS stock’s Bonum Health product is now offered in 500 stores across all 50 states, increasing accessibility to its thousands of customers.

    MEDS Stock’s Partnerships

    MEDS stock also secured a group purchasing agreement with QualityCare Pharmacies, an independent pharmacy prescription drug buying group. QualityCare is the newest part of the company’s rapidly expanding GPO offering, aimed to drive substantial gains in wallet share amongst independent pharmacies on the TRxADE platform. MEDS stock also launched a government-oriented health passport solution with an accompanying mobile app, facilitating the expedition of post-Covid-19 reopening.

    MEDS Stock Revenue Reports

    Revenues for Q2 2021 were up to USD$1.9 million, down from the USD$6.6 million in the same quarter of the prior year. This year-over-year decrease was largely driven by non-recurring sales of personal protective equipment (PPE) in the 2020 quarter, in relation to global efforts to manage the outbreak of the Covid-19 pandemic.

    Additional Financials

    The second quarter of 2021 saw MEDS stock report gross profits in the amount of USD$0.8 million, representing 44.3% of the quarter’s revenues. This is comparable to the USD$2 million reported for the prior-year quarter, representing 30.4% of revenues. The substantial year-over-year increase in gross profit margin was largely driven by fewer lower margin PPE sales in the 2021 quarter. Operating expenses for the second quarter of 2021 came in at USD$3.4 million, up from the USD$2.5 million reported in the prior-year quarter. This increase was largely driven by an inventory investment loss of USD$1.2 million.

    Future Outlook for MEDS

    Armed with its expanding network of strategic collaborations and the success of its most recent financial reports, MEDS stock is poised to continue its trajectory of success. The company is keen to allocate resources so as to usher in further growth, with investors hoping for long-term increases in shareholder value.

  • Gaotu Techedu Inc. (GOTU) Stock Plummets Following Rising Oversight and Involvement by Chinese Government in Private Education Sector

    Gaotu Techedu Inc. (GOTU) stock prices plummeted by 24.72% some time after market trading commenced on July 26th, 2021, bringing the price per share down to USD$2.65 early on in the trading day.

    New Regulations

    China recently announced a massive set of new regulations for private education companies, primarily aimed at decreasing workloads for students. The government mandates were also designed to overhaul a marketspace that it claims has been “hijacked by capital”. The regulations ban companies such as GOTU stock that adhere to school curriculums from generating profits, raising capital, or going public. School-related tutoring can no longer be offered on weekends or during vacations. They also cannot give classes to children under the age of six, a demographic that has been increasingly pushed to start studying from an earlier age.

    GOTU Stock in Changed Landscape

    The Chinese education technology sector reached a value of USD$100 billion as companies like GOTU stock catered to the increasing number of parents wanting to give their children an early academic advantage. The regulation changes will see business models being drastically altered as companies are forced into making extensive changes in order to maintain compliance. The drastic change will see the prohibition of the overseas investments that have been the lifeblood of the sector. Companies that find themselves in violation of the new regulations are required to rectify the situation, as appropriate.

    Details of Regulations

    The private education sector attracted billions of dollars and was expected to generate USD$76 billion in revenue by 2024, of which GOTU stock hoped to be a part. The regulatory branch that aims to regulate the industry was formed in June 2021 and aims to devise and oversee the changes. The regulations were expressed in general terms, with broad applicability to common practices throughout the industry. The regulations are directed at compulsory subjects, with supplementary subjects such as art and music avoiding falling under the umbrella of the new regulations.

    Government Involvement

    The regulations were jointly announced on July 24th, 2021 by the General Office of the Communist Party of China Central Committee and the General Office of the State Council. The set of rulings aims to mitigate the excess associated with homework and after-school tutoring for students as young as six who are receiving mandatory education.

    Future Outlook for GOTU Stock

    As one of the many up and coming companies that is forced to make adjustments to adhere to the new regulations, GOTU stock is keen to capitalize on the education sector being disrupted. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Youdao, Inc. (DAO) Stock Plummets Following Increase in Chinese Government Regulations for Educational Institutions

    Youdao, Inc. (DAO) stock prices plummeted by 29.58% shortly after market trading commenced on July 26th, 2021, bringing the price per share down to USD$8.95 early on in the trading day.

    New Guidelines for DAO Stock

    July 24th, 2021 saw the General Office of the Communist Party of China Central Committee and the General office of the State Council collaboratively issue a set of guidelines. These guidelines aim to reduce the prevalence of excessive homework and after-school tutoring for students receiving compulsory education.

    Guideline Restrictions

    The guidelines will require all institutions offering online after-school tutoring on academic subjects in compulsory education register themselves as non-profit organizations. The institutions are also required to obtain approval from the relevant regulatory authorities. The guidelines also made it compulsory to comply with various operational requirements in regard to class hours, faculty qualifications, tuition standards, advertising, and others.

    DAO Stock Explores Alternative Funding

    Furthermore, the guidelines prohibit any and all institutions from generating capital through stock exchange listings or other capital-related activities. Also prohibited are foreign investments in school curriculum-based tutoring institutions through variable interest entity arrangements, mergers, and acquisitions. Companies that are listed are prohibited from raising capital through equity offerings, with violations already having taken place expected to be corrected as appropriate.

    Working to Maintain Compliance

    While the interpretation and implementation of the guidelines are not yet completely concretized, they are expected to have material impacts on DAO stock’s K-12 course business, financial condition, and corporate structure. The company continues to investigate ways to comply with the newly introduced requirements for its K-12 course business. It will also continue to work with regulatory authorities in a bid to improve operations while staying in strict compliance with all laws and regulations. DAO also hopes to fulfill its social responsibilities, facilitating the provision of high-quality, innovative products and services to its customers. This will promote the long-term development of the education industry in China.

    Future Outlook for DAO Stock

    With an expanding umbrella of regulations and restrictions that they now have to maneuver, DAO stock is poised to capitalize on the disruption caused in the marketspace. The company is keen to regain and maintain compliance in a big to consolidate and expand its market footprint. Investors are hopeful that management will be able to effectively generate funds to fund the continue trajectory of the company’s success.